Combination Therapy Offers Limited Additional Benefit in Type 2 Diabetes
Taking two common types of type 2 diabetes medications together might not protect your heart or kidneys any better…
-
-
Stopping GLP-1 Drugs May Raise Mental Health Risks in Type 2 Diabetes Patients
New research shows that people who stop taking GLP-1 receptor agonist drugs may face a higher risk of mental…
-
Phase 3 Trial Evaluates Retatrutide for Type 2 Diabetes and Weight Management
A new phase 3 trial shows that retatrutide significantly improves blood sugar control. The study also confirms notable weight…
-
GLP-1 Receptor Agonists and Urinary Incontinence in Women With Obesity and Type 2 Diabetes
Urinary incontinence affects a significant number of women who are obese and have type 2 diabetes. Extra body fat…
-
Rybelsus Oral Tablets Expand GLP-1 Access for Type 2 Diabetes Patients
The oral form of semaglutide is the first widely available glucagon-like peptide-1 receptor agonist that does not require an…
-
Seven Pharmacological Options for Weight Management
Obesity affects many adults today. It leads directly to heart disease, diabetes, and joint pain. Because of this, doctors…
-
Medicare’s New GLP-1 Bridge Program: Seven Essential Clinical and Coverage Facts
Medicare made a notable policy change on July 1 by extending limited coverage for weight management medications through the…
-
New Research Suggests GLP-1 Drugs Could Help Reduce Aggressive Tendencies
Glucagon-like peptide-1 receptor agonists have completely changed how doctors manage type 2 diabetes and obesity. Daily medications like Ozempic,…
-
Why Your Body Needs Extra Nutrients While on Weight-Loss Medications
New weight-loss drugs are changing how doctors treat obesity and type 2 diabetes. Medications like semaglutide and tirzepatide help…
-
Shame and Stigma Affect the GLP-1 Treatment Journey
Weight stigma has a measurable impact on clinical outcomes during pharmacological treatment for obesity. Glucagon-like peptide-1 receptor agonists, like…
